The DOI matches its Crossref record; 914 of the 914 references it cites were found in a registry or an index.
Human prostate cancer risk factors
Open accessAbstract
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with similar likelihood of neoplastic foci found within the prostates of men around the world regardless of diet, occupation, lifestyle, or other factors. Essentially all men with circulating androgens will develop microscopic prostate cancer if they live long enough. This review is a contemporary and comprehensive, literature-based analysis of the putative risk factors for human prostate cancer, and the results were presented at a multidisciplinary consensus conference held in Crystal City, Virginia, in the fall of 2002. The objectives were to evaluate known environmental factors and mechanisms of prostatic carcinogenesis and to identify existing data gaps and future research needs. The review is divided into four sections, including 1) epidemiology (endogenous factors [family history, hormones, race, aging and oxidative stress] and exogenous factors [diet, environmental agents, occupation and other factors, including lifestyle factors]); 2) animal and cell culture models for prediction of human risk (rodent models, transgenic models, mouse reconstitution models, severe combined immunodeficiency syndrome mouse models, canine models, xenograft models, and cell culture models); 3) biomarkers in prostate cancer, most of which have been tested only as predictive factors for patient outcome after treatment rather than as risk factors; and 4) genotoxic and nongenotoxic mechanisms of carcinogenesis. The authors conclude that most of the data regarding risk relies, of necessity, on epidemiologic studies, but animal and cell culture models offer promise in confirming some important findings. The current understanding of biomarkers of disease and risk factors is limited. An understanding of the risk factors for prostate cancer has practical importance for public health research and policy, genetic and nutritional education and chemoprevention, and prevention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 801–914 of 914
Calcium, dairy products, and the risk of prostate cancer
Tavani, A., Gallus, S., Franceschi, S., & Vecchia, C. L. (2001) · The Prostate · doi:10.1002/pros.1087 · Cited by 41
Is the androgen receptor CAG repeat length significant for prostate cancer?
Giovannucci, E. L. (2002) · PubMed · Cited by 41
Allison, J., Zhang, Y., & Parker, M. G. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.5.2254-2257.1989 · Cited by 41
Establishment and Characterization of a New Human Prostatic Carcinoma Cell Line (DuPro-1)
Gingrich, J. R., Tucker, J. A., Walther, P. J., Day, J. W., Poulton, S. H. M., & Webb, K. S. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)37960-0 · Cited by 41
Rokhlin, O. W., Guseva, N. V., Taghiyev, A. F., Glover, R. A., & Cohen, M. B. (2002) · The Prostate · doi:10.1002/pros.10074 · Cited by 40
Gain in Chromosome 8q Correlates with Early Progression in Hormonal Treated Prostate Cancer
Steiner, T., Junker, K., Burkhardt, F., Braunsdorf, A., Janitzky, V., & Schubert, J. (2002) · European Urology · doi:10.1016/s0302-2838(01)00030-6 · Cited by 40
SZOSTAK, M. J., KAUR, P., Amin, P. P., et al. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66306-9 · Cited by 40
The contribution of inhibins and activins to malignant prostate disease
Risbridger, G. P., Mellor, S. L., McPherson, S. J., & Schmitt, J. F. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00497-x · Cited by 40
Shan, J., Porvari, K., Ruokonen, M., Karhu, A., Launonen, V., Hedberg, P. S. M., Oikarinen, J., & Vihko, P. (1997) · Endocrinology · doi:10.1210/en.138.9.3764 · Cited by 40
van Schaik, R. H. N., Wierikx, C. D. J., Timmerman, M. A., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0886 · Cited by 39
Pergolizzi, R. G., Kreis, W., Rottach, C., Susin, M., & Broome, J. D. (1993) · Cancer Investigation · doi:10.3109/07357909309020257 · Cited by 39
Drew, L., Fine, R. L., Tamara, N., Douglas, G. P., & Petrylak, D. P. (2002) · PubMed · Cited by 39
Ho, S., Leav, I., Ghatak, S., Merk, F. B., Jagannathan, V. S., & Mallery, K. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65553-8 · Cited by 39
Self-citationKanoh, Y., Akahoshi, T., Ohara, T., Ohtani, N., Mashiko, T., Ohtani, S., Egawa, S., & Baba, S. (2002) · PubMed · Cited by 39
Plasma Chromogranin a in Prostatic Carcinoma and Neuroendocrine Tumors
Kimura, N., Hoshi, S., Takahashi, M., et al. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)65203-0 · Cited by 39
Arenas, M. I., Romo, E., Royuela, M., Fraile, B., & Paniagua, R. T. (2000) · The Histochemical Journal · doi:10.1023/a:1004111331752 · Cited by 38
Role of Nerve Growth Factor‐like Protein in the Paracrine Regulation of Prostate Growth
Djakiew, D. (1992) · Journal of Andrology · doi:10.1002/j.1939-4640.1992.tb00341.x · Cited by 38
Self-citationProstate cancer and other xenografts from cells in peripheral blood of patients.
Pretlow, T. G., Schwartz, S. H., Giaconia, J. M., et al. (2000) · PubMed · Cited by 38
Draper, H. H., Agarwal, S., Nelson, D. E. V., Wee, J., Ghoshal, A. K., & Farber, E. (1995) · Lipids · doi:10.1007/bf02537489 · Cited by 38
Wilson, E., Oh, Y., Hwa, V., & Rosenfeld, R. G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4504 · Cited by 38
Her-2/neu Expression in Prostate Cancer
Carles, J., Lloreta, J., Salido, M., Pous, A. F., Suarez, M., Baena, V., Nogué, M., Domènech, M., & Fabregat, X. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0115 · Cited by 38
Wu, A. H., Whittemore, A. S., Kolonel, L. N., Stanczyk, F. Z., John, E. M., Gallagher, R. P., & West, D. W. (2001) · PubMed · Cited by 38
Expression of p75 LNGFR and Trk neurotrophin receptors in normal and neoplastic human prostate
Guate, Fernández, Lanzas, Escaf, & Vega (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00155.x · Cited by 37
Fribourg, A. F., Knudsen, K. E., Strobeck, M. W., Lindhorst, C. M., & Knudsen, E. S. (2000) · PubMed · Cited by 37
Yu, M., Zhang, Y., Blaner, W. S., & Santella, R. M. (1994) · Cancer · Cited by 37
The human androgen receptor: Structure/function relationship in normal and pathological situations
Brinkmann, A. O., Jenster, G. W., Kuiper, G. G. J. M., Ris‐Stalpers, C., van Laar, J. H., van der Korput, J. A. G. M., DEGENHART, H. J., Trifiro, M. A., Pinsky, L., Romalo, G., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90362-m · Cited by 37
Case‐control study of prostatic cancer in Kyoto, Japan: Demographic and some lifestyle risk factors
Oishi, K., Okada, K., Yoshida, O., Yamabe, H., Ohno, Y., Hayes, R. B., & Schroeder, F. H. (1989) · The Prostate · doi:10.1002/pros.2990140205 · Cited by 37
Effects of long-term ?-tocopherol supplementation on serum hormones in older men
Hartman, T. J., Dorgan, J. F., Woodson, K. G., Virtamo, J. R. K., Tangrea, J. A., Heinonen, O. P., Taylor, P. R., Barrett, M. J., & Albanes, D. (2001) · The Prostate · doi:10.1002/1097-0045(200101)46:1<33::aid-pros1005>3.0.co;2-6 · Cited by 36
Cancer Mortality Among Mormons in California During 1968–75 1 2
Enstrom, J. E. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.5.1073 · Cited by 36
Yu, M. S., Leav, B. A., Leav, I., Merk, F. B., Wolfe, H. J., & Ho, S. (1993) · PubMed · Cited by 36
Self-citationTumor suppressor genes in prostatic oncogenesis.
Bookstein, R. (1994) · PubMed · Cited by 36
Anti‐Proliferative Effect of the Kinase Inhibitor K252a on Human Prostatic Carcinoma Cell Lines
Delsite, R., & Djakiew, D. (1996) · Journal of Andrology · doi:10.1002/j.1939-4640.1996.tb01824.x · Cited by 35
Self-citationThorburn, J., Bender, L. M., Morgan, M. J., & Thorburn, A. M. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-04-0207 · Cited by 35
A novel human cancer culture model for the study of prostate cancer
Yasunaga, Y., Nakamura, K., Ko, D., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1205002 · Cited by 35
Matikainen, M. P., Schleutker, J., Mörsky, P. J., Kallioniemi, O., & Tammela, T. L. J. (1999) · PubMed · Cited by 34
Hereditary Prostate Cancer and Other Genetic Predispositions to Prostate Cancer
Cussenot, O., Valéri, A., Berthon, P., Fournier, G., & Mangin, P. (1998) · Urologia Internationalis · doi:10.1159/000056549 · Cited by 34
STRAVODIMOS, K. G., Constantinides, C. A., MANOUSAKAS, T., Pavlaki, C., Pantazopoulos, D., Giannopoulos, A., & Dimopoulos, C. (2000) · PubMed · Cited by 33
IncreasedRB1 abnormalities in human primary prostate cancer following combined androgen blockade
Mack, P. C., Chi, S.-G., Meyers, F. J., STEWART, S. L., White, R. D., & Gumerlock, P. H. (1998) · The Prostate · Cited by 33
Taneja, S. S., Ha, S., & Garabedian, M. J. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1278 · Cited by 33
Malins, D. C., Polissar, N. L., & Gunselman, S. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3611 · Cited by 33
Presnell, S. C., Werdin, E. S., Maygarden, S. J., Mohler, J. L., & Smith, G. J. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61761-0 · Cited by 32
Reduced circulating androgen bioactivity in patients with prostate cancer
Raivio, T., Santti, H., Schatzl, G., et al. (2003) · The Prostate · doi:10.1002/pros.10234 · Cited by 32
Mottaz, A. E., Markwalder, R. V., Fey, M. F., Klima, I., Merz, V. W., Thalmann, G. N., Ball, R. K., & Studer, U. E. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970601)31:4<223::aid-pros3>3.0.co;2-l · Cited by 32
Fraction of prostate cancer incidence attributed to diet in Athens, Greece
Bosetti, C., Τζώνου, Α., Λάγιου, Π., Negri, E., Trichopoulos, D., & Hsieh, C.-C. (2000) · European Journal of Cancer Prevention · doi:10.1097/00008469-200004000-00008 · Cited by 32
Role of prostate stem cell antigen in prostate cancer research
Jalkut, M. W., & Reiter, R. E. (2002) · Current Opinion in Urology · doi:10.1097/00042307-200209000-00006 · Cited by 32
Tissue Injury by Free Radicals
Cheeseman, K. H. (1993) · Toxicology and Industrial Health · doi:10.1177/0748233793009001-205 · Cited by 32
Mori, T., Imaida, K., Tamano, S., Sano, M., Takahashi, S., Asamoto, M., Takeshita, M., Ueda, H., & Shirai, T. (2001) · Japanese journal of cancer research : Gann · doi:10.1111/j.1349-7006.2001.tb01056.x · Cited by 31
Tamano, S., Rehm, S., Waalkes, M. P., & Ward, J. M. (1996) · Veterinary Pathology · doi:10.1177/030098589603300511 · Cited by 31
Case–control study of alcohol consumption and prostate cancer risk in Montréal, Canada
Sharpe, C. R., & Siemiatycki, J. (2001) · Cancer Causes & Control · doi:10.1023/a:1011289108040 · Cited by 30
Inhibin-related proteins in rat prostate
Risbridger, G. P., Thomas, T. Z., Gurusinghe, C. J., & McFarlane, J. R. (1996) · Journal of Endocrinology · doi:10.1677/joe.0.1490093 · Cited by 30
Glucuronosyltransferase activity in human cancer cell line LNCaP
Guillemette, C., & Bélanger, A. (1995) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)03434-u · Cited by 30
Inhibition of prostate cancer growth by estramustine and colchicine
Fakih, M., Replogle‐Schwab, T. S., Lehr, J. E., Pienta, K. J., & Yagoda, A. (1995) · The Prostate · doi:10.1002/pros.2990260606 · Cited by 30
Isolation of two genomic sequences encoding the Mr = 14,000 subunit of rat prostatein.
Viskochil, D. H., Perry, S. T., Lea, O. A., Stafford, D. W., Wilson, E. M., & French, F. S. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32135-5 · Cited by 29
Irani, J., Lefebvre, O., Murat, F., Dahmani, L., & Dore, B. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04133.x · Cited by 29
Hietanen, E. K., Bartsch, H., Béréziat, J., Ahotupa, M. O., Camus, A. ‐., Cabral, J. R., & Laitinen, M. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460415 · Cited by 29
Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?
Xue, Y., Smedts, F. M. M., Latijnhouwers, M. A., Ruijter, E., Aalders, T. W., de la Rosette, J. J. M. C. H., Debruyne, F. M. J., & Schalken, J. A. (1998) · PubMed · Cited by 29
Bjelfman, C., Söderström, T. G., Brekkan, E., Norlén, B. J., Egevad, L., Unge, T., Andersson, S., & Rane, A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4080 · Cited by 29
Transforming growth factor-? and prostate cancer
Steiner, M. S. (1995) · World Journal of Urology · doi:10.1007/bf00191213 · Cited by 29
Co-expression of hepatocyte growth factor and its receptor in human prostate cancer
Kurimoto, S., Moriyama, N., Horie, S., Sakai, M., Kameyama, S., Akimoto, Y., Hirano, H., & Kawabe, K. (1998) · The Histochemical Journal · doi:10.1023/a:1003262412346 · Cited by 28
Jiang, F., Yang, L.-P., Cai, X., Cyriac, J., Shechter, I., & Wang, Z. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00086-3 · Cited by 28
Characterization of ALVA-41 cells, a new human prostatic cancer cell line
Nakhla, A. M., & Rosner, W. (1994) · Steroids · doi:10.1016/0039-128x(94)90052-3 · Cited by 28
Sigala, S., Tognazzi, N., Rizzetti, M. C., Faraoni, I., Missale, C., Bonmassar, E., & Spano, P. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470407 · Cited by 28
Lamm, M. L. G., Sintich, S. M., & Lee, C. (1998) · Endocrinology · doi:10.1210/endo.139.2.5907 · Cited by 27
Kinetic analysis of androstenedione 5α-reductase in epithelium and stroma of human prostate
Weißer, H., & Krieg, M. (1997) · Steroids · doi:10.1016/s0039-128x(97)00042-1 · Cited by 27
Saeed, B., Zhang, H., & Ng, S. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970515)31:3<198::aid-pros9>3.0.co;2-h · Cited by 26
Prognostic significance of T antigen expression in patients with gastric carcinoma
Chung, Y. S., Yamashita, Y., Kato, Y., Nakata, B., Sawada, T., & Sowa, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960501)77:9<1862::aid-cncr16>3.0.co;2-y · Cited by 25
Birnbaum, R. S., Ware, J. L., & Plymate, S. R. (1994) · Journal of Endocrinology · doi:10.1677/joe.0.1410535 · Cited by 25
Liu, B. C. ‐., LaRose, I., Weinstein, L. J., Ahn, M., Weinstein, M. H., & Richie, J. P. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1943::aid-cncr1713>3.0.co;2-m · Cited by 25
Maliner, M. S., Klein, R. D., Udayakumar, T. S., Nagle, R. B., & Bowden, G. T. (2001) · Neoplasia · doi:10.1038/sj.neo.7900178 · Cited by 25
Billström, A., Dahllöf, B., Hartley‐Asp, B., Lecander, I., Dagnæs‐Hansen, F., & Stenram, U. (1995) · The Prostate · doi:10.1002/pros.2990260206 · Cited by 25
Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma
Szende, B., Romics, I., Minik, K., Szabó, J., Torda, I., Lovász, S., Szomor, L., Tóth, L., Bely, M., Kerënyi, T., et al. (2001) · The Prostate · doi:10.1002/pros.1122 · Cited by 25
Uchida, K., Chaudhary, L. R., Sugimura, Y., Adkisson, H. D., & Hruska, K. A. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10327 · Cited by 25
Crocitto, L. E., Henderson, B. E., & Coetzee, G. A. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64287-3 · Cited by 25
Bossyns, D., Delaey, B. M., Rombauts, W., & Heyns, W. (1986) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(86)90840-x · Cited by 24
Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats
Pollard, M. (1996) · Cancer Letters · doi:10.1016/0304-3835(95)04105-2 · Cited by 24
Yano, T., Pinski, J., Szepesházi, K., et al. (1992) · The Prostate · doi:10.1002/pros.2990200405 · Cited by 24
Rudolfsson, S. H., Stattin, P. E., Wikström, P., Bergh, A. R. J., & Damber, J. (2001) · British Journal of Urology · doi:10.1046/j.1464-410x.2001.02234.x · Cited by 23
Hereditary aspects of prostate cancer.
McLellan, D. L., & Norman, R. W. (1995) · Europe PMC (PubMed Central) · Cited by 23
Bostwick, D. G., Norlén, B. J., & Denis, L. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655900750169257-1 · Cited by 23
Self-citationExpression of the Type 1 and Type 2 Steroid 5α-Reductases in Human Fetal Tissues
Ellsworth, K. P., & Harris, G. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2530 · Cited by 23
Establishment and characterization of monoclonal antibody against androgen receptor
Takayoshi, D., Kuzumaki, N., Atsushi, O., Fujita, H., Teruo, I., & Koyanagi, T. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90231-8 · Cited by 23
Family History of Breast Cancer as a Predictor for atal Prostate Cancer
Rodríguez, C., Calle, E. E., Tatham, L. M., Wingo, P. A., Heidi, L., Miracle-McMahill, Thun, M. J., & Heath, C. W. (1998) · Epidemiology · doi:10.1097/00001648-199809000-00009 · Cited by 23
Kim, H. E., Han, S. J., Kasza, T., Han, R., Choi, H.-S., Palmer, K. C., & Kim, H.-R. C. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00358-1 · Cited by 22
Oncogene overexpression and de novo drug-resistance in human prostate cancer cells
Yamazaki, H., Schneider, E., Myers, C. E., & Sinha, B. K. (1994) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(94)90063-9 · Cited by 22
Middleman, M. N., Lush, R. M., & Figg, W. D. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02967.x · Cited by 21
Joint Effects of Smoking and Body Mass Index on Prostate Cancer Risk
Sharpe, C. R., & Siemiatycki, J. (2001) · Epidemiology · doi:10.1097/00001648-200109000-00014 · Cited by 21
Asbell, S. O., Raimane, K. C., Montesano, A. T., Zeitzer, K. L., Asbell, M. D., & Vijayakumar, S. (2000) · PubMed Central · Cited by 21
Hormones and gynecologic cancer
Gurpide, E. (1976) · Cancer · doi:10.1002/1097-0142(197607)38:1<382::aid-cncr2820380155>3.0.co;2-v · Cited by 19
Developmental stage sensitivity and mode of action information for androgen agonists and antagonists
Euling, S. Y., & Kimmel, C. A. (2001) · The Science of The Total Environment · doi:10.1016/s0048-9697(01)00736-7 · Cited by 19
Self-citationThe epidemiology of cancer of the prostate
Higgins, I. T. T. (1975) · Journal of Chronic Diseases · doi:10.1016/0021-9681(75)90029-6 · Cited by 19
Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens
Wang, Z., Ramin, S. A., Tsai, C. K., Lui, P. D., Ruckle, H. C., Beltz, R. E., & Sands, J. F. (2001) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(00)00102-2 · Cited by 19
Han, K., Viallet, J., Chevalier, S., Zheng, W., Bazinet, M., & Aprikian, A. G. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970401)31:1<61::aid-pros10>3.0.co;2-m · Cited by 19
Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?
Čulig, Z., Hobisch, A., Hittmair, A., Peterziel, H., Radmayr, C., Bartsch, G., Cato, A. C. B., & Klocker, H. (1997) · PubMed · Cited by 19
Heeno, E., Biesenbach, P., Englund, C., Lund, M., Toft, A., & Lund, L. C. (2021) · Scandinavian Journal of Urology · doi:10.1080/21681805.2021.1906317 · Cited by 18
Okada, K., Yokoyama, K., Okihara, K., Ukimura, O., Kojima, M., Miki, T., & Takamatsu, T. (2001) · Urology · doi:10.1016/s0090-4295(00)00907-9 · Cited by 17
An appraisal of telomerase activity in benign prostatic hyperplasia
Caldarera, E., Crooks, N. H., Muir, G., Pavone‐Macaluso, M., & Carmichael, P. L. (2000) · The Prostate · doi:10.1002/1097-0045(20001101)45:3<216::aid-pros3>3.0.co;2-c · Cited by 17
Signaling Inhibitors in the Treatment of Prostate Cancer
Hudes, G. R. (2002) · Investigational New Drugs · doi:10.1023/a:1015678427111 · Cited by 16
Geick, A., Redecker, P., Ehrhardt, A., Klocke, R., Paul, D., & Halter, R. (2001) · Transgenic Research · doi:10.1023/a:1013085228119 · Cited by 16
Treatment of Androgen-Independent Prostate Cancer
Bubley, G. J., & Balk, S. P. (1996) · The Oncologist · doi:10.1634/theoncologist.1-1-30 · Cited by 16
Androgen-selective gene regulation in the prostate
Haendler, B. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00159-7 · Cited by 16
Partial growth suppression of human prostate cancer cells by the Krev‐1 suppressor gene
Burney, T. L., Rockove, S., Eiseman, J. L., Jacobs, S. C., & Kyprianou, N. (1994) · The Prostate · doi:10.1002/pros.2990250403 · Cited by 16
He, P., & YASUMOTO, K. (1994) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(94)90006-x · Cited by 16
Colombel, M. C., DIEZ, S. G., Radvanyi, F., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb16228.x · Cited by 15
Arguments against the prostatic origin of the R-3327 Dunning H tumor
Goebel, H.-W., Rausch, U., Steinhoff, M. S., Seitz, J., Bacher, M., Papotti, M. G., Bussolati, G., Tuohimaa, P., & Aumüller, G. (1992) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02899660 · Cited by 15
Lane, K. E., Ricci, M. J., & Ho, S. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970301)30:4 · Cited by 14
Self-citationEpidemiology of prostate cancer and bladder cancer: an overview
Ross, R. K. (1996) · Cancer treatment and research · doi:10.1007/978-1-4615-6343-3_1 · Cited by 13
Height and the survival of prostate cancer patients.
Chen, H., Miller, B. A., Giovannucci, E. L., & Hayes, R. B. (2003) · PubMed · Cited by 13
LeRoy, B. E., Bahnson, R. R., & Rosol, T. J. (2002) · The Prostate · doi:10.1002/pros.10037 · Cited by 12
Gleave, M. E., & Miyake, H. (2000) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500440 · Cited by 11
van Helden, P., Wiid, I. J. F., Helden, E. H.-V., Bey, E., & Cohen, R. J. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.279 · Cited by 10
Catz, S. D., BABIOR, B. M., & Johnson, J. L. (2002) · Biochemical Journal · doi:10.1042/bj20020345 · Cited by 10
Kikuchi, E., Nakashima, J., Horiguchi, Y., Oya, M., Ohigashi, T., & Murai, M. (2003) · The Journal of Urology · doi:10.1016/s0022-5347(05)64003-7 · Cited by 7
Venkatesh (1989) · doi:10.1002/1097-0142(19890801)64:3
(1995) · PubMed
Research works printed but not linked: 902
- Oishi, 1995, Cancer Surv., 23, 267
- Parkin, 1992, IARC Sci Publ., 120, 45
- Doherty, 1996, Br J Hosp Med., 55, 104
- Morrison, 1995, Can J Public Health., 86, 274
- Dijkman, 1996, Eur Urol., 30, 281, 10.1159/000474185 · doi:10.1159/000474185
- Wingo, 1998, Cancer Epidemiol Biomarkers Prev., 7, 271
- Merrill, 1996, J Natl Cancer Inst., 88, 1683, 10.1093/jnci/88.22.1683 · doi:10.1093/jnci/88.22.1683
- Mettlin, 1996, Cancer., 77, 150, 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19960101)77:1<150::aid-cncr25>3.0.co;2-3
- Brawley, 1997, Cancer., 80, 1857, 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19971101)80:9<1857::aid-cncr26>3.0.co;2-3
- Wingo, 1997, Cancer., 80, 1810, 10.1002/(SICI)1097-0142(19971101)80:9<1810::AID-CNCR19>3.0.CO;2-8 · doi:10.1002/(sici)1097-0142(19971101)80:9<1810::aid-cncr19>3.0.co;2-8
- Levy, 1993, CMAJ., 149, 617
- Smart, 1997, CA Cancer J Clin., 47, 134, 10.3322/canjclin.47.3.134 · doi:10.3322/canjclin.47.3.134
- Pienta, 1995, Urology., 45, 93, 10.1016/S0090-4295(95)96996-9 · doi:10.1016/s0090-4295(95)96996-9
- Dhom, 1983, J Cancer Res Clin Oncol., 106, 210, 10.1007/BF00402610 · doi:10.1007/bf00402610
- Polednak, 1997, Cancer., 79, 99, 10.1002/(SICI)1097-0142(19970101)79:1<99::AID-CNCR14>3.0.CO;2-1 · doi:10.1002/(sici)1097-0142(19970101)79:1<99::aid-cncr14>3.0.co;2-1
- Newman, 1996, Radiol Technol., 68, 39
- Bostwick, 1992, Cancer., 70, 291, 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4 · doi:10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4
- Partin, 1994, Urology., 44, 646, 10.1016/S0090-4295(94)80197-5 · doi:10.1016/s0090-4295(94)80197-5
- Bostwick, 2000, Curr Urol Rep., 1, 65, 10.1007/s11934-000-0037-x · doi:10.1007/s11934-000-0037-x
- Bostwick, 1987, Cancer., 59, 788, 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I · doi:10.1002/1097-0142(19870215)59:4<788::aid-cncr2820590421>3.0.co;2-i
- Montironi, 1996, Eur Urol., 30, 133, 10.1159/000474162 · doi:10.1159/000474162
- Allam, 1996, Mod Pathol., 9, 742
- Qian, 1997, Hum Pathol., 28, 143, 10.1016/S0046-8177(97)90097-6 · doi:10.1016/s0046-8177(97)90097-6
- Feneley, 1997, Prostate Cancer Prostatic Dis., 1, 79, 10.1038/sj.pcan.4500210 · doi:10.1038/sj.pcan.4500210
- Sakr, 1997, Eur Urol., 32, 15
- Keetch, 1995, J Urol., 154, 347, 10.1016/S0022-5347(01)67044-7 · doi:10.1016/s0022-5347(01)67044-7
- Raviv, 1996, Acta Urol Belgium., 64, 11
- Rovner, 1997, J Urol., 158, 138, 10.1097/00005392-199707000-00042 · doi:10.1097/00005392-199707000-00042
- Davidson, 1995, J Urol., 154, 1295, 10.1016/S0022-5347(01)66840-X · doi:10.1016/s0022-5347(01)66840-x
- Shepherd, 1996, J Urol., 156, 460, 10.1016/S0022-5347(01)65881-6 · doi:10.1016/s0022-5347(01)65881-6
- Langer, 1996, J Urol., 155, 228, 10.1016/S0022-5347(01)66601-1 · doi:10.1016/s0022-5347(01)66601-1
- Bostwick, 1996, Eur Urol., 30, 145, 10.1159/000474164 · doi:10.1159/000474164
- Bostwick, 1996, Cancer., 78, 330, 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W · doi:10.1002/(sici)1097-0142(19960715)78:2<330::aid-cncr22>3.0.co;2-w
- Ferguson, 1994, Urology., 44, 91, 10.1016/S0090-4295(94)80015-4 · doi:10.1016/s0090-4295(94)80015-4
- Aquilina, 1997, J Natl Cancer Inst., 89, 689, 10.1093/jnci/89.10.689 · doi:10.1093/jnci/89.10.689
- Colombel, 1993, Am J Pathol., 143, 390
- Goldstein, 1995, Hum Pathol., 26, 887, 10.1016/0046-8177(95)90012-8 · doi:10.1016/0046-8177(95)90012-8
- Saez, 1998, Mod Pathol., 11, 1193
- Papadopoulos, 2001, Clin Cancer Res., 7, 1533
- Kirschenbaum, 1999, Mol Urol., 3, 163
- Molberg, 1994, Am J Clin Pathol., 101, 266, 10.1093/ajcp/101.3.266 · doi:10.1093/ajcp/101.3.266
- Shah, 2001, Arch Pathol Lab Med., 125, 141, 10.5858/2001-125-0141-HAHCOS · doi:10.5858/2001-125-0141-hahcos
- Bostwick, 1995, Arch Pathol Lab Med., 119, 444
- Varma, 2002, Arch Pathol Lab Med., 126, 554, 10.5858/2002-126-0554-MCFTDO · doi:10.5858/2002-126-0554-mcftdo
- Egan, 1997, Am J Surg Pathol., 21, 931, 10.1097/00000478-199708000-00007 · doi:10.1097/00000478-199708000-00007
- Zhou, 2001, Am J Clin Pathol., 115, 39, 10.1309/2APJ-YKBD-97EH-67GW · doi:10.1309/2apj-ykbd-97eh-67gw
- Bonin, 1997, Cancer., 79, 75, 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19970101)79:1<75::aid-cncr11>3.0.co;2-3
- Ozcan, 2001, Eur Urol., 40, 308, 10.1159/000049791 · doi:10.1159/000049791
- D'Amico, 2001, J Urol., 165, 126, 10.1097/00005392-200101000-00031 · doi:10.1097/00005392-200101000-00031
- Nelson, 2002, Urology., 59, 740, 10.1016/S0090-4295(02)01654-0 · doi:10.1016/s0090-4295(02)01654-0
- O'Malley, 2002, Urology., 59, 85, 10.1016/S0090-4295(01)01486-8 · doi:10.1016/s0090-4295(01)01486-8
- Freedland, 2002, J Urol., 167, 516, 10.1016/S0022-5347(01)69076-1 · doi:10.1016/s0022-5347(01)69076-1
- Sebo, 2001, Cancer., 91, 2196, 10.1002/1097-0142(20010601)91:11<2196::AID-CNCR1249>3.0.CO;2-# · doi:10.1002/1097-0142(20010601)91:11<2196::aid-cncr1249>3.0.co;2-#
- Merrick, 2002, Cancer J., 8, 79, 10.1097/00130404-200201000-00014 · doi:10.1097/00130404-200201000-00014
- Bahnson, 1989, Prostate., 15, 149, 10.1002/pros.2990150208 · doi:10.1002/pros.2990150208
- Montironi, 1993, Virchows Arch A Pathol Anat Histopathol., 422, 185, 10.1007/BF01621801 · doi:10.1007/bf01621801
- Weidner, 1993, Am J Pathol., 143, 401
- Brawer, 1994, Cancer., 73, 678, 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO;2-6 · doi:10.1002/1097-0142(19940201)73:3<678::aid-cncr2820730329>3.0.co;2-6
- Hall, 1994, Urology., 44, 869, 10.1016/S0090-4295(94)80173-8 · doi:10.1016/s0090-4295(94)80173-8
- Vesalainen, 1994, Anticancer Res., 14, 709
- Epstein, 2000, Urology., 56, 283, 10.1016/S0090-4295(00)00640-3 · doi:10.1016/s0090-4295(00)00640-3
- Silberman, 1997, Cancer., 79, 772, 10.1002/(SICI)1097-0142(19970215)79:4<772::AID-CNCR14>3.0.CO;2-X · doi:10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x
- de la Taille, 2000, Am J Clin Pathol., 113, 555, 10.1309/02W2-KE50-PKEF-G2G4 · doi:10.1309/02w2-ke50-pkef-g2g4
- Stamey, 1999, JAMA., 281, 1395, 10.1001/jama.281.15.1395 · doi:10.1001/jama.281.15.1395
- van den Ouden, 1998, Urol Int., 60, 17, 10.1159/000030197 · doi:10.1159/000030197
- McNeal, 1996, Am J Surg Pathol., 20, 1351, 10.1097/00000478-199611000-00006 · doi:10.1097/00000478-199611000-00006
- Mehta, 2001, Clin Cancer Res., 7, 81
- Whittemore, 1995, Am J Epidemiol., 141, 732, 10.1093/oxfordjournals.aje.a117495 · doi:10.1093/oxfordjournals.aje.a117495
- Klein, 1998, Prostate Cancer Prostatic Dis., 1, 297, 10.1038/sj.pcan.4500257 · DOI
- Damber, 1998, Int J Cancer., 78, 293, 10.1002/(SICI)1097-0215(19981029)78:3<293::AID-IJC5>3.0.CO;2-Q · doi:10.1002/(sici)1097-0215(19981029)78:3<293::aid-ijc5>3.0.co;2-q
- Bratt, 1999, Eur J Cancer., 35, 272, 10.1016/S0959-8049(98)00358-X · doi:10.1016/s0959-8049(98)00358-x
- Cerhan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 53
- Lightfoot, 2000, Ann Epidemiol., 10, 470, 10.1016/S1047-2797(00)00112-5 · doi:10.1016/s1047-2797(00)00112-5
- Kalish, 2000, Urology., 56, 803, 10.1016/S0090-4295(00)00780-9 · DOI
- Kotsis, 2002, J Urol., 167, 1659, 10.1016/S0022-5347(05)65173-7 · doi:10.1016/s0022-5347(05)65173-7
- Cotter, 2002, Prostate., 50, 216, 10.1002/pros.10051 · doi:10.1002/pros.10051
- Stone, 2003, Ethn Dis., 13, 233
- Gronberg, 1999, Cancer., 86, 477, 10.1002/(SICI)1097-0142(19990801)86:3<477::AID-CNCR16>3.0.CO;2-K · doi:10.1002/(sici)1097-0142(19990801)86:3<477::aid-cncr16>3.0.co;2-k
- Schuurman, 1999, Epidemiology., 10, 192, 10.1097/00001648-199903000-00020 · doi:10.1097/00001648-199903000-00020
- McLellan, 1995, CMAJ., 153, 895
- Staples, 2003, Cancer Causes Control., 14, 161, 10.1023/A:1023073203467 · doi:10.1023/a:1023073203467
- Matikainen, 1999, Clin Cancer Res., 5, 1275
- Thiessen, 1974, Cancer., 34, 1102, 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5 · doi:10.1002/1097-0142(197410)34:4<1102::aid-cncr2820340421>3.0.co;2-5
- Anderson, 1992, J Natl Cancer Inst., 84, 1114, 10.1093/jnci/84.14.1114 · doi:10.1093/jnci/84.14.1114
- Andrieu, 1991, Eur J Cancer., 27, 244, 10.1016/0277-5379(91)90506-9 · doi:10.1016/0277-5379(91)90506-9
- Henderson, 1982, Cancer Res., 42, 3232
- Ghanadian, 1979, Br J Cancer., 39, 696, 10.1038/bjc.1979.122 · doi:10.1038/bjc.1979.122
- Vatten, 1997, Cancer Epidemiol Biomarkers Prev., 6, 967
- Nomura, 1996, Cancer Epidemiol Biomarkers Prev., 5, 621
- Guess, 1997, Cancer Epidemiol Biomarkers Prev., 6, 21
- Chang, 2001, Prostate., 46, 62, 10.1002/1097-0045(200101)46:1<62::AID-PROS1009>3.0.CO;2-V · doi:10.1002/1097-0045(200101)46:1<62::aid-pros1009>3.0.co;2-v
- Stattin, 2001, J Clin Endocrinol Metab., 86, 1341
- Ross, 1986, J Natl Cancer Inst., 76, 45
- Barrett-Connor, 1990, Cancer Res., 50, 169
- Jackson, 1981, Progr Clin Biol Res., 53, 111
- Modugno, 2001, Clin Cancer Res., 7, 3092
- Haenszel, 1968, J Natl Cancer Inst., 40, 43
- Locke, 1980, J Natl Cancer Inst., 65, 1149
- Stellman, 1994, Cancer., 73, 1270, 10.1002/1097-0142(19940215)73:4<1270::AID-CNCR2820730423>3.0.CO;2-Y · doi:10.1002/1097-0142(19940215)73:4<1270::aid-cncr2820730423>3.0.co;2-y
- Merrill, 2000, Urology., 55, 730, 10.1016/S0090-4295(99)00564-6 · doi:10.1016/s0090-4295(99)00564-6
- Abdalla, 1998, Semin Urol Oncol., 16, 207
- Asbell, 2000, J Natl Med Assoc., 92, 445
- Zhang, 2000, J Urol., 163, 131, 10.1016/S0022-5347(05)67988-8 · doi:10.1016/s0022-5347(05)67988-8
- Fowler, 2000, J Urol., 163, 1467, 10.1016/S0022-5347(05)67644-6 · doi:10.1016/s0022-5347(05)67644-6
- Wu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 533
- Reichardt, 1995, Cancer Res., 55, 3973
- Platz, 1999, Cancer Epidemiol Biomarkers Prev., 8, 1107
- Winter, 2001, Urology., 58, 614, 10.1016/S0090-4295(01)01273-0 · doi:10.1016/s0090-4295(01)01273-0
- Ekman, 1999, Prostate., 39, 262, 10.1002/(SICI)1097-0045(19990601)39:4<262::AID-PROS6>3.0.CO;2-P · doi:10.1002/(sici)1097-0045(19990601)39:4<262::aid-pros6>3.0.co;2-p
- Corder, 1995, Cancer Epidemiol Biomarkers Prev., 4, 655
- Yamada, 2001, Int J Cancer., 92, 683, 10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4 · doi:10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4
- Leadon, 1990, Health Phys., 59, 15, 10.1097/00004032-199007000-00001 · doi:10.1097/00004032-199007000-00001
- Statland, 1992, Clin Chem., 38, 1587
- Palmiter, 1987, Experientia., 52, 63
- Yu, 1994, Cancer., 73, 596, 10.1002/1097-0142(19940201)73:3<596::AID-CNCR2820730316>3.0.CO;2-N · doi:10.1002/1097-0142(19940201)73:3<596::aid-cncr2820730316>3.0.co;2-n
- Hietanen, 1994, Eur J Clin Nutr., 48, 575
- Hietanen, 1991, Carcinogenesis., 12, 591, 10.1093/carcin/12.4.591 · doi:10.1093/carcin/12.4.591
- Clark, 1996, JAMA., 276, 1957, 10.1001/jama.1996.03540240035027 · DOI · Paper page
- Han, 1995, Carcinogenesis., 16, 951, 10.1093/carcin/16.4.951 · doi:10.1093/carcin/16.4.951
- Schuurman, 1999, Cancer., 86, 1019, 10.1002/(SICI)1097-0142(19990915)86:6<1019::AID-CNCR18>3.0.CO;2-H · doi:10.1002/(sici)1097-0142(19990915)86:6<1019::aid-cncr18>3.0.co;2-h
- Berg, 1975, Cancer Res., 35, 3345
- Blair, 1978, J Natl Cancer Inst., 61, 1379
- Ohno, 1988, Cancer Res., 48, 1331
- Mettlin, 1989, Cancer., 64, 605, 10.1002/1097-0142(19890801)64:3<605::AID-CNCR2820640307>3.0.CO;2-I · doi:10.1002/1097-0142(19890801)64:3<605::aid-cncr2820640307>3.0.co;2-i
- Hayes, 1999, Cancer Epidemiol Biomarkers Prev., 8, 25
- Graham, 1983, J Natl Cancer Inst., 70, 687
- Ross, 1987, J Natl Cancer Inst., 78, 869
- Severson, 1989, Cancer Res., 49, 1857
- Mills, 1989, Cancer., 64, 598, 10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6 · doi:10.1002/1097-0142(19890801)64:3<598::aid-cncr2820640306>3.0.co;2-6
- Hirayama, 1979, Natl Cancer Inst Monogr., 53, 149
- Hsing, 1990, Cancer Res., 50, 6836
- De Stefani, 2000, Cancer Epidemiol Biomarkers Prev., 9, 335
- Harvei, 1997, Int J Cancer., 71, 545, 10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U · doi:10.1002/(sici)1097-0215(19970516)71:4<545::aid-ijc7>3.0.co;2-u
- Bishop, 1988, Immunogenetics., 28, 184, 10.1007/BF00375858 · doi:10.1007/bf00375858
- Sporn, 1984, J Natl Cancer Inst., 73, 1381
- Kummet, 1983, Semin Oncol., 10, 281
- Olsen, 1996, Ugeskr Laeger., 158, 3171
- Kolonel, 1987, Cancer Res., 47, 2982
- Ellison, 1998, Chron Dis Can., 19, 1
- Paganini-Hill, 1987, J Natl Cancer Inst., 79, 443
- Hayes, 1988, Cancer., 62, 2021, 10.1002/1097-0142(19881101)62:9<2021::AID-CNCR2820620925>3.0.CO;2-R · doi:10.1002/1097-0142(19881101)62:9<2021::aid-cncr2820620925>3.0.co;2-r
- Reichman, 1990, Cancer Res., 50, 2311
- Wald, 1986, Br J Cancer., 54, 957, 10.1038/bjc.1986.267 · doi:10.1038/bjc.1986.267
- Nomura, 1997, Cancer Epidemiol Biomarkers Prev., 6, 487
- Cook, 1999, Cancer., 86, 1783, 10.1002/(SICI)1097-0142(19991101)86:9<1783::AID-CNCR21>3.0.CO;2-N · doi:10.1002/(sici)1097-0142(19991101)86:9<1783::aid-cncr21>3.0.co;2-n
- Lu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 749
- Hirayama, 1986, Gan No Rinsho., 32, 610
- Clinton, 1999, Cancer., 86, 1629, 10.1002/(SICI)1097-0142(19991101)86:9<1629::AID-CNCR1>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19991101)86:9<1629::aid-cncr1>3.0.co;2-4
- Eichholzer, 1999, Prostate., 38, 189, 10.1002/(SICI)1097-0045(19990215)38:3<189::AID-PROS3>3.0.CO;2-N · doi:10.1002/(sici)1097-0045(19990215)38:3<189::aid-pros3>3.0.co;2-n
- Schwartz, 1990, Anticancer Res., 10, 1307
- Corder, 1993, Cancer Epidemiol Biomarkers Prev., 2, 467
- Peehl, 1999, Eur Urol., 35, 392, 10.1159/000019914 · doi:10.1159/000019914
- Suzuki, 2003, Int J Urol., 10, 261, 10.1046/j.1442-2042.2003.00617.x · doi:10.1046/j.1442-2042.2003.00617.x
- Schwartz, 1998, Cancer Epidemiol Biomarkers Prev., 7, 391
- Gann, 1996, Cancer Epidemiol Biomarkers Prev., 5, 121
- Schwartz, 1994, Anticancer Res., 14, 1077
- Chan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 893
- Liang, 1999, Prostate., 40, 200, 10.1002/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3 · doi:10.1002/(sici)1097-0045(19990801)40:3<200::aid-pros8>3.0.co;2-3
- Feustel, 1986, Prostate., 8, 75, 10.1002/pros.2990080109 · doi:10.1002/pros.2990080109
- Leake, 1984, Acta Endocrinol (Copenhagen)., 105, 281, 10.1530/acta.0.1050281 · doi:10.1530/acta.0.1050281
- Whelan, 1983, Br J Urol., 55, 525, 10.1111/j.1464-410X.1983.tb03362.x · doi:10.1111/j.1464-410x.1983.tb03362.x
- Chirulescu, 1987, Med Interne., 25, 257
- Ogunlewe, 1989, Cancer., 63, 1388, 10.1002/1097-0142(19890401)63:7<1388::AID-CNCR2820630725>3.0.CO;2-M · doi:10.1002/1097-0142(19890401)63:7<1388::aid-cncr2820630725>3.0.co;2-m
- Lekili, 1991, Int Urol Nephrol., 23, 151, 10.1007/BF02549712 · doi:10.1007/bf02549712
- McCallum, 1988, Br J Urol., 62, 565, 10.1111/j.1464-410X.1988.tb04427.x · doi:10.1111/j.1464-410x.1988.tb04427.x
- Feustel, 1989, Urol Res., 17, 41
- Tvedt, 1989, Prostate., 15, 41, 10.1002/pros.2990150105 · doi:10.1002/pros.2990150105
- Elghany, 1990, Epidemiology., 1, 107, 10.1097/00001648-199003000-00005 · doi:10.1097/00001648-199003000-00005
- Goodman, 2001, Cancer Epidemiol Biomarkers Prev., 10, 1069
- Nomura, 2000, Cancer Epidemiol Biomarkers Prev., 9, 883
- Grant, 1999, Altern Med Rev., 4, 162
- Rodriguez, 2003, Cancer Epidemiol Biomarkers Prev., 12, 597
- Balaji, 2001, Prostate., 48, 265, 10.1002/pros.1106 · doi:10.1002/pros.1106
- Sung, 1999, Cancer., 86, 484, 10.1002/(SICI)1097-0142(19990801)86:3<484::AID-CNCR17>3.0.CO;2-P · doi:10.1002/(sici)1097-0142(19990801)86:3<484::aid-cncr17>3.0.co;2-p
- Hsieh, 1999, Int J Cancer., 80, 699, 10.1002/(SICI)1097-0215(19990301)80:5<699::AID-IJC12>3.0.CO;2-7 · doi:10.1002/(sici)1097-0215(19990301)80:5<699::aid-ijc12>3.0.co;2-7
- van der Gulden, 1994, Br J Urol., 73, 382, 10.1111/j.1464-410X.1994.tb07601.x · doi:10.1111/j.1464-410x.1994.tb07601.x
- Kolonel, 1977, Lancet., 2, 566, 10.1016/S0140-6736(77)90714-0 · doi:10.1016/s0140-6736(77)90714-0
- Schuman, 1977, Cancer Treat Rep., 61, 181
- Niijima, 1980, Scand J Urol Nephrol., 55, 177
- Newell, 1998, Vet Radiol Ultrasound., 39, 332, 10.1111/j.1740-8261.1998.tb01616.x · doi:10.1111/j.1740-8261.1998.tb01616.x
- Talamini, 1993, Prev Med., 22, 400, 10.1006/pmed.1993.1033 · doi:10.1006/pmed.1993.1033
- Hayes, 1994, Cancer Causes Control., 5, 221, 10.1007/BF01830240 · doi:10.1007/bf01830240
- Lumey, 1997, Prostate., 33, 195, 10.1002/(SICI)1097-0045(19971101)33:3<195::AID-PROS8>3.0.CO;2-I · doi:10.1002/(sici)1097-0045(19971101)33:3<195::aid-pros8>3.0.co;2-i
- Giles, 2001, Ann Oncol., 12, 761, 10.1023/A:1011131105617 · doi:10.1023/a:1011131105617
- Plaskon, 2003, Cancer Epidemiol Biomarkers Prev., 12, 604
- Lotufo, 2000, Int J Cancer., 87, 141, 10.1002/1097-0215(20000701)87:1<141::AID-IJC21>3.0.CO;2-A · doi:10.1002/1097-0215(20000701)87:1<141::aid-ijc21>3.0.co;2-a
- Whittemore, 1985, J Natl Cancer Inst., 74, 43
- Carstensen, 1987, J Epidemiol Commun Health., 41, 166, 10.1136/jech.41.2.166 · DOI
- Giovannucci, 1999, Cancer Epidemiol Biomarkers Prev., 8, 277
- Colditz, 1996, Cancer Causes Control., 7, 560, 10.1007/BF00051890 · doi:10.1007/bf00051890
- Yu, 1997, Cancer Detect Prev., 21, 497
- Verhoeven, 1996, Cancer Epidemiol Biomarkers Prev., 5, 733
- Schuurman, 1998, Cancer Epidemiol Biomarkers Prev., 7, 673
- Kolonel, 2000, Cancer Epidemiol Biomarkers Prev., 9, 795
- Lee, 2003, Cancer Epidemiol Biomarkers Prev., 12, 665
- Gann, 1999, Cancer Res., 59, 1225
- Clinton, 1996, Cancer Epidemiol Biomarkers Prev., 5, 823
- Imaida, 2001, Carcinogenesis., 22, 467, 10.1093/carcin/22.3.467 · doi:10.1093/carcin/22.3.467
- Watson, 1995, Environ Health Perspect., 103, 41
- Soto, 1995, Environ Health Perspect., 103, 113
200 of 902 shown
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Hormones, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm323 · Cited by 786
Tang, W.-Y., Morey, L. M., Cheung, Y. Y., Birch, L., Prins, G. S., & Ho, S.-M. (2012) · Endocrinology · doi:10.1210/en.2011-1308 · Cited by 164
Self-citationBarrington, W. E., Schenk, J. M., Etzioni, R., Arnold, K. B., Neuhouser, M. L., Thompson, I. M., Lucia, M. S., & Kristal, A. R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0513 · Cited by 107
Metadata
- Authors
- Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S.-M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., & Timms, B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004
- Volume
- 101
- Issue
- S10
- Pages
- 2371-2490
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2121518362
- Cited by
- 650
- References
- 914
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4261 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.